Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease.

@article{Pagan2018EngineeredSO,
  title={Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease.},
  author={Jose D Pagan and Maya Kitaoka and Robert M. Anthony},
  journal={Cell},
  year={2018},
  volume={172 3},
  pages={
          564-577.e13
        }
}
Self-reactive IgGs contribute to the pathology of autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. Paradoxically, IgGs are used to treat inflammatory diseases in the form of high-dose intravenous immunoglobulin (IVIG). Distinct glycoforms on the IgG crystallizable fragment (Fc) dictate these divergent functions. IgG anti-inflammatory activity is attributed to sialylation of the Fc glycan. We therefore sought to convert endogenous IgG to anti-inflammatory… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 158 times over the past 90 days. VIEW TWEETS
5 Citations
84 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 84 references

Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease

  • Pagan
  • Cell (2018),
  • 2017

Similar Papers

Loading similar papers…